Cargando…
Epigenetic therapy in urologic cancers: an update on clinical trials
Epigenetic dysregulation is one of many factors that contribute to cancer development and progression. Numerous epigenetic alterations have been identified in urologic cancers including histone modifications, DNA methylation changes, and microRNA expression. Since these changes are reversible, effor...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Impact Journals LLC
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355359/ https://www.ncbi.nlm.nih.gov/pubmed/28036257 http://dx.doi.org/10.18632/oncotarget.14226 |